Explore CanVasc and its affiliated centers across Canada
CanVasc is the Canadian network for research on vasculitides. It was created in November 2010 by Drs. Pagnoux, Carette and Khalidi. The first task was to identify referral medical centers and physicians across Canada with expertise in vasculitis and who were willing to be part of this new research group (core members). Among its several other aims, important ones are to help conduct studies on vasculitis, provide support and educational material on vasculitides for physicians and other health care professionals and, eventually, optimize the therapeutic management of patients with these rare diseases.
CLICK HERE for more information on CanVasc.
CLICK HERE for more information on national CanVasc meetings
CanVasc recommendations for the management of ANCA-associated vasculitides
One of the objectives of CanVasc is too harmonize and optimize the treatment of patients with vasculitides and, eventually, improve their outcomes, wherever they live in Canada. The development of recommendations will help achieve this goal. Starting in 2013, CanVasc core members had been working hard to develop the first Canadian recommendations for the management of ANCA-associated vasculitides. They were published in November 2015 in the Journal of Rheumatology (link HERE), with an executive summary in the Canadian Journal of Kidney Health and Disease (link HERE).
An updated version of these recommendations will be published in late 2019 - early 2020.
The 2nd edition of the CanVasc-CAVALI teaching book will be distributed in April 2019!
CanVasc printed out in March 2017 its first educational book on vasculitides (400 ex.), based on practical clinical case-scenarios, the CAVALI book (CanVasc learning initiative). Batches of books, free for residents and physicians, were sent to every local CanVasc core members (currently out of stock). You can still download, by clicking here, the first 8 pages of the book (1st Edition).
A new and entirely updated edition of the book has been printed (800 ex. this time) and sent out to CanVasc centers and interested core members in the Spring 2019. Contact your local core member to get a copy.
Review studies on vasculitis actively recruiting in Canada
Several prospective studies on vasculitis are ongoing across the world, including in several Canadian centers. Have a brief overview of these latter ones, including ARAMIS, CUTIS, ABROGATE and TAPIR on the study webpage and determine whether your patients could participate in any of them.
PATIENTS can also ENROLL THEMSELVES directly into the VCRC contact registry or the V-PPRN research network! Several studies are ongoing and rolling already with the active participation of patients leaving in North America, including some studies led by CanVasc researchers! See the links to these registry and network and get more information on this very innovative way to conduct patient-oriented research on the Link page.
Update your knowledge on vasculitis with CanVasc online materials
FDA APPROVES RITUXIMAB FOR MAINTENANCE. October 2018.
JAKinibs for GCA? May 2018.
The results of PEXIVAS have been released on May 25th. May 2018.
MAINRITSAN 1 long-term and MAINRISTAN 2 articles are published. May 2018.
Health Canada now also approves tocilizumab for the treatment of GCA. October 2017.
FDA approves tocilizumab for the treatment of GCA. June 2017.
Download some presentations given by CanVasc members at conferences and meetings:
go to the Meeting page
Become a CanVasc member
If you are a health care provider interested in vasculitis and CanVasc activities, you can register by simply sending us an email (email@example.com), specifying your name, surname, profession, address and full affiliations. At this time, membership is free and does not imply anything (please note that core, associated and affiliated member status is for physicians already identified by the CanVasc bureau).
You may receive occasional information by email on the CanVasc meetings or studies. CanVasc is a non-profit scientific network. You will not receive any unsollicited mailing from other companies or groups.